Search research articles
Contact Us
Filters
Showing results (201-210 of 211) with videos related to
Page
of 22
Sort By:
Cancer Medicine
|
June 21, 2026
Concomitant Medication Effects on Immunotherapy Outcomes in Sarcoma: A Pooled Post Hoc Analysis of Seven Phase II Trials
Adel Shahnam, Kristen DiConza, Simran Jasnani, et al.
Nature Immunology
|
May 7, 2013
Natural and inducible TH17 cells are regulated differently by Akt and mTOR pathways
Jiyeon S Kim, Tammarah Sklarz, Lauren B Banks, et al.
Trends in Ecology & Evolution
|
May 14, 2023
The ethics of intervening in animal behaviour for conservation
Thom van Dooren, Catherine J Price, Peter B Banks, et al.
Journal for Immunotherapy of Cancer
|
September 5, 2025
High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapy
Benjamin A Nacev, Martina Bradic, Hyung Jun Woo, et al.
Nature Medicine
|
April 28, 2022
Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA
Smita S Chandran, Jiaqi Ma, Martin G Klatt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 15, 2024
Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma
Sujana Movva, Kenneth Seier, Viswatej Avutu, et al.
Journal for Immunotherapy of Cancer
|
May 4, 2026
Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma
Evan Rosenbaum, Kenneth Seier, Rodrigo Gularte-Mérida, et al.
Journal for Immunotherapy of Cancer
|
June 13, 2025
Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma
Sujana Movva, Kenneth Seier, Martina Bradic, et al.
Plos Pathogens
|
June 14, 2012
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7
Nicholas F Parrish, Craig B Wilen, Lauren B Banks, et al.
Cancer Research Communications
|
December 1, 2025
Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
Evan Rosenbaum, Rodrigo Gularte-Mérida, Evan Seffar, et al.
Page
of 22
Search research articles
Search
Showing results (201-210 of 211) with videos related to
Sort By:
Page
of 22
Cancer Medicine
|
June 21, 2026
Concomitant Medication Effects on Immunotherapy Outcomes in Sarcoma: A Pooled Post Hoc Analysis of Seven Phase II Trials
Adel Shahnam, Kristen DiConza, Simran Jasnani, et al.
Nature Immunology
|
May 7, 2013
Natural and inducible TH17 cells are regulated differently by Akt and mTOR pathways
Jiyeon S Kim, Tammarah Sklarz, Lauren B Banks, et al.
Trends in Ecology & Evolution
|
May 14, 2023
The ethics of intervening in animal behaviour for conservation
Thom van Dooren, Catherine J Price, Peter B Banks, et al.
Journal for Immunotherapy of Cancer
|
September 5, 2025
High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapy
Benjamin A Nacev, Martina Bradic, Hyung Jun Woo, et al.
Nature Medicine
|
April 28, 2022
Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA
Smita S Chandran, Jiaqi Ma, Martin G Klatt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 15, 2024
Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma
Sujana Movva, Kenneth Seier, Viswatej Avutu, et al.
Journal for Immunotherapy of Cancer
|
May 4, 2026
Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma
Evan Rosenbaum, Kenneth Seier, Rodrigo Gularte-Mérida, et al.
Journal for Immunotherapy of Cancer
|
June 13, 2025
Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma
Sujana Movva, Kenneth Seier, Martina Bradic, et al.
Plos Pathogens
|
June 14, 2012
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7
Nicholas F Parrish, Craig B Wilen, Lauren B Banks, et al.
Cancer Research Communications
|
December 1, 2025
Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
Evan Rosenbaum, Rodrigo Gularte-Mérida, Evan Seffar, et al.
Page
of 22